Ahmed O. Alenazi is a critical care clinical pharmacist, Al Imam Abdulrahman Bin Faisal Hospital, Dammam, Saudi Arabia.
Zahra M. Alhalimi was a PharmD student at Al Imam Abdulrahman Bin Faisal University, Dammam, at the time of writing this article.
Crit Care Nurse. 2021 Feb 1;41(1):25-30. doi: 10.4037/ccn2021400.
Hyponatremia and neurocritical injury are life-threatening conditions requiring immediate management with consideration of the safety concerns related to peripheral intravenous administration of hypertonic solutions. Although a central intravenous catheter is the preferred route of administration, central intravenous catheters have many complications and can potentially delay medication administration in urgent situations.
To evaluate the safety and efficacy of continuous infusion of 3% hypertonic saline via peripheral intravenous administration in critically ill adult patients.
Data were collected from PubMed and Web of Science from database inception to April 7, 2019. Included studies involved adult patients with hyponatremia and/or neurocritical situations and compared administration of 3% hypertonic saline via peripheral administration with standard supportive care (administration through a central intravenous catheter).
Of 502 articles identified, 7 were included in the review. Three articles were retrospective studies, 2 were prospective studies, 1 was a case series, and 1 was a case report. Infusion-related adverse events and electrolyte abnormalities due to 3% hypertonic saline administration through a peripheral intravenous catheter were minimal and were limited to phlebitis, erythema, edema, hyperchloremia, and hypokalemia with administration at a high infusion rate (83.3 mL/h) and for a prolonged duration (≥ 6 hours). Infusion rate, duration, catheter gauge, and catheter placement may have a role in infusion-related adverse events.
Current recommendations to administer continuous infusions of 3% hypertonic saline through a central intravenous catheter should be reassessed. Peripheral intravenous administration can be used safely and effectively in patients in critical situations.
低钠血症和神经危重症是危及生命的病症,需要立即进行治疗,同时考虑外周静脉输注高渗溶液的安全性问题。虽然中心静脉导管是首选的给药途径,但中心静脉导管有许多并发症,在紧急情况下可能会延迟药物的给药。
评估在危重症成年患者中通过外周静脉持续输注 3%高渗盐水的安全性和疗效。
数据来源于 PubMed 和 Web of Science,检索时间截至 2019 年 4 月 7 日。纳入的研究涉及低钠血症和/或神经危重症的成年患者,比较了外周静脉输注 3%高渗盐水与标准支持治疗(通过中心静脉导管给药)的疗效。
在 502 篇文章中,有 7 篇被纳入综述。其中 3 篇为回顾性研究,2 篇为前瞻性研究,1 篇为病例系列研究,1 篇为病例报告。通过外周静脉导管输注 3%高渗盐水引起的与输注相关的不良事件和电解质异常非常少见,仅限于静脉炎、红斑、水肿、高氯血症和低钾血症,这些不良事件与高输注率(83.3 mL/h)和长时间输注(≥ 6 小时)有关。输注率、输注时间、导管规格和导管放置位置可能与输注相关的不良事件有关。
目前建议通过中心静脉导管给予连续输注 3%高渗盐水,这一建议应重新评估。在危急情况下,外周静脉给药可以安全有效地使用。